Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Rang in Aktien #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Aktienkurs
$150.78
Zuletzt synchronisiert: 2026-09-18
Marktkapitalisierung
$187.20B
Veränderung (1 Tag)
-0.08%
Veränderung (1 Jahr)
32.15%
Land
US
Handel Gilead Sciences, Inc. (GILD)

Kategorie

P/B-Verhältnis für Gilead Sciences, Inc. (GILD)
P/B-Verhältnis zum September 2026 TTM: 15.39
Laut den neuesten Finanzberichten und dem Aktienkurs von Gilead Sciences, Inc. beträgt das aktuelle Kurs-Buchwert-Verhältnis (TTM) 15.39. Am Ende des Jahres 2024 lag das P/B-Verhältnis bei 5.96.
P/B-Verlauf für Gilead Sciences, Inc. von 2000 bis 2026
P/B-Verhältnis zum Jahresende
Jahr P/B-Verhältnis ändert
2026 (TTM) 15.39 -100.00%
2025 0.00 -100.00%
2024 5.96 34.58%
2023 4.43 -12.71%
2022 5.07 17.19%
2021 4.33 7.59%
2020 4.02 9.82%
2019 3.66 -3.49%
2018 3.80 -17.12%
2017 4.58 -9.78%
2016 5.08 -36.48%
2015 7.99 -14.05%
2014 9.30 -7.89%
2013 10.10 68.83%
2012 5.98 27.09%
2011 4.71 -11.06%
2010 5.29 -13.96%
2009 6.15 -44.20%
2008 11.02 -10.79%
2007 12.35 -24.75%
2006 16.42 108.13%
2005 7.89 -2.41%
2004 8.08 -30.89%
2003 11.69 0.49%
2002 11.64 -15.83%
2001 13.83 28.66%
2000 10.75 0.00%
P/B-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/B-Verhältnis P/B-Verhältnis-Differenz Land
29.9692 94.78%
US
7.6479 -50.29%
US
-78.0908 -607.54%
US
8.4776 -44.90%
CH
8.5385 -44.51%
US